Therapies for Down Syndrome Regression Disorder

Down Syndrome Clinical Trial

Official title:

Mechanistic Investigation of Therapies for Down Syndrome Regression Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05662228
• Other study ID #: 22-1992
• Status: Recruiting
• Phase: Phase 2
• Start date: June 29, 2023
• Est. completion date: December 2026

Study information

• Verified date: March 2024
• Source: University of Colorado, Denver
• Contact: Angela Rachubinski, PhD
• Phone: 303-724-7366
• Email: DSresearch[@]cuanschutz.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Individuals with Down syndrome (DS) have an increased risk of numerous co-occurring conditions, including the neuropsychiatric condition known as Down Syndrome Regression Disorder (DSRD). A DSRD diagnosis often includes a sub-acute onset of catatonia, mutism, depersonalization, loss of ability to perform activities of daily living, hallucinations, delusions, and aggression and is most commonly observed in adolescents and young adults.

The study evaluates the safety and efficacy of three currently prescribed therapies:

lorazepam, intravenous immunoglobulin (IVIG) and tofacitinib.

Description:

Recent published case reports and clinical experience of the investigators indicate Down Syndrome Regression Disorder (DSRD) may be successfully treated with immune-modulating therapies, in addition to current pharmacologic options. This study is a multidimensional clinical trial designed to advance the understanding of the etiology of DSRD and to evaluate the safety and efficacy of three distinct therapeutic approaches to treating DSRD: (1) the benzodiazepine lorazepam (Ativan™) (2) intravenous immunoglobulin (IVIG, Gammagard™) or (3) the JAK inhibitor tofacitinib (Xeljanz™). Participants will be randomized into one of the three treatment arms above for the 12-week study period, with a subset of participants undergoing an initial 12-week observational period.

Specific Aims:

1. To define the relative safety profile of lorazepam, IVIG, and tofacitinib in DSRD.

2. To compare the efficacy of lorazepam, IVIG, and tofacitinib in DSRD.

3. To investigate potential mechanisms underlying DSRD and its response to therapies.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 66
• Est. completion date: December 2026
• Est. primary completion date: December 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 8 Years to 30 Years

Eligibility

Inclusion Criteria:

• Individuals with DS between the ages of 8 and 30 years, inclusive. DS is broadly defined to include complete trisomy 21, Robertsonian translocation trisomy 21, partial trisomy 21 (segmental duplication), and mosaic trisomy 21.

• Diagnosis of possible or probable DSRD per 2022 consensus guidelines.

• Must agree to random treatment assignment.

• Must agree to complete a washout of any medications intended to treat symptoms of DSRD or that may interfere with study interventions.

• Must be able to present with a study partner or legal guardian at all study visits.

Exclusion Criteria:

General

• Weight less than 40 kg.

• Pregnant or breast feeding.

• Past or current tobacco smoking.

• Poor venous access not allowing repeated blood tests or non-compliance with venipuncture requirements.

• Known allergies, hypersensitivity, or intolerance to lorazepam, IVIG, or tofacitinib.

• Participants may be excluded for other unforeseen reasons or confounding reasons for DSRD symptoms at the study doctor's discretion.

Co-occurring Conditions

• Any co-occurring genetic disorder.

• Active symptomatic cardiac disease.

• Clinically significant chronic or active viral infection, including but not limited to HIV, hepatitis, CMV, EBV, HSV or untreated tuberculosis.

• Untreated chronic or active bacterial infection.

• Untreated hypothyroidism or hyperthyroidism.

• History of disseminated herpes zoster, disseminated herpes simplex, or recurrent localized dermatomal herpes zoster.

• History of malignancy (solid tumor or leukemia).

• Moyamoya syndrome or stroke (active or prior).

• Baseline abnormal renal function indicative of moderate or severe renal disease by eGFR <=45.

• History of acute narrow-angle glaucoma.

• History of venous or arterial thrombosis.

• IgA deficiency with antibodies against IgA.

• Pathogenic neuronal autoantibody positivity against established causes of autoimmune encephalopathy in CSF.

• Any subject with a history of anaphylaxis or a severe systemic response to blood or plasma-derived products.

Medications or Interventions

• Any vaccination planned during the study or within the last 6 weeks.

• Use of electroconvulsive therapy, lorazepam, or a JAK inhibitor within the last 4 weeks.

• Use of IVIG within the last 8 weeks.

• Use of immunosuppressant drugs (e.g., prednisone, mycophenolate mofetil, azathioprine) within the last 8 weeks.

• Use of rituximab within the past 6 months, unless B cell levels have recovered and are above 50 cells/uL.

• Use of other immunosuppressant biologics (e.g., adalimumab, etanercept) within the past 6 months.

• Use of strong CP3A4 inhibitors or inducers (e.g., ketoconazole, rifampin) within the last 4 weeks.

• Use of moderate CP3A4 inhibitors with a strong CYP2C19 inhibitor (e.g., fluconazole) within the last 4 weeks.

• Use of moderate CYP2C9 inhibitors (e.g., valproic acid) within the last 4 weeks.

• Use of strong CYP1A2 inducers (e.g., phenobarbital) or moderate CYP1A2 inhibitors (e.g., fluvoxamine) within the last 4 weeks.

• Use of certain mood stabilizers or anticonvulsants (e.g., clonazepam, lithium, oxcarbazepine) within the last 4 weeks.

• Any prior use of methotrexate, cyclophosphamide, or other chemotherapeutics.

• Any prior solid organ transplant.

• Any prior neurosurgical intervention.

• Any subject who has received blood or plasma products = 30 days prior to first Baseline visit.

Related Conditions & MeSH terms

• Down Syndrome
• Syndrome

Intervention

Drug:
• Lorazepam
Lorazepam will be administered as an oral pill over the first 15 days of study in a daily titration, starting at 0.5 mg BID and increasing to up to 2 mg three times daily, as tolerated. Dosing will continue at the maximum tolerated dose through the 12-week endpoint. Participants will be titrated off lorazepam over at least four weeks after completing the endpoint visit. Taper will be tailored to individuals for safety reasons with a goal of decreasing dosage by 25% weekly. Phone check ins will be conducted every three days to monitor patient.
• Intravenous immunoglobulin (IVIG)
IVIG will be administered as a series of four intravenous infusions at a dose of 1 mg/kg with pre-infusion medications of 1 mg/kg diphenhydramine and 15 mg/kg acetaminophen. The first two infusions occur at baseline and one day after (induction dosing), followed by one infusion at 4 weeks and one infusion at 8 weeks.
• Tofacitinib
Tofacitinib will be administered as an oral pill at 5 mg twice daily over the 12-week study.

Locations

Country	Name	City	State
United States	Children's Hospital Colorado	Aurora	Colorado
United States	Children's Hospital Los Angeles	Los Angeles	California

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	Children's Hospital Los Angeles

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Change in minutes of total sleep and longest sleep as measured by FitBit.	Change in the sleep as monitored by FitBit watch recordings within or between treatment arms. To include total amount of minutes of sleep in a 24-hour period over an average of seven days, longest block of sleep in a 24-hour period over an average of seven days, and total sleep minutes between 8 pm and 8 am.	Baseline to 12 weeks
Other	Change in social interaction as measured by SRS-2 subdomain T-scores.	Change in Social Responsiveness Scale-2 (SRS-2) subdomain treatment T-scores within or between treatment arms. A decrease in score indicates improvement.	Baseline to 12 weeks
Other	Change in behavior as measured by DBC-2 T-score.	A statistically significant change in Developmental Behavioral Checklist-2 (DBC-2) T-scores within or between treatment arms. A decrease in score indicates improvement.	Baseline to 12 weeks
Other	Change in one or more measures of overall cognitive ability.	A statistically significant change in one or more measures of overall cognitive ability within or between treatment arms.; Measures include: Behavior Rating Inventory of Executive Function, 2nd Edition (BRIEF-2): Change in T-scores.; Down Syndrome Mental Status Exam (DSMSE): Change in Total Memory and Non-Memory Composite score. .; Cambridge Neuropsychological Test Automated Battery (CANTAB) Paired Associate Learning (PAL) subdomain will be used to measure episodic learning.; CANTAB Spatial Span (SS) will be used to measure spatial processing.; CANTAB Reaction Time Interval (RTI) subdomain will be used to measure processing speed.; Kaufman Brief Intelligence Test-2 Revised (KBIT-2 Revised): Change in Standard Score.; Neuropsychiatric Inventory (NPI): Change in total score.	Baseline to 12 weeks
Other	Change in receptive language as measured by PVT raw score.	Change in the raw score of the NIH Toolbox Picture Vocabulary Test (PVT). An increase in score indicates an improved performance.	Baseline to 12 weeks
Primary	Comparison of number and severity of all adverse events.	A summary of adverse events (AEs) by type and organ system will be reported for the entire study period, along with any statistically significant differences observed in rates of AEs across treatment arms.	Baseline to 14 weeks
Secondary	Change in catatonia by overall score in BFCRS.	Change in overall score in the Bush-Francis Catatonia Rating Scale (BFCRS) between baseline and 12 weeks within or between treatment arms. A decrease in score indicates an improved performance.	Baseline to 12 weeks
Secondary	Time to complete 25-Foot Walk assessment.	Change in the time it takes to complete walking 25 feet between baseline to 12 weeks. A decrease in score indicates an improved performance.	Baseline to 12 weeks
Secondary	Total number of errors in visual motor assessment NEPSY-II.	Using NEPSY-II to measure change in total number of errors between both car and motorcycle trials. A decrease in score indicates an improved performance.	Baseline to 12 weeks
Secondary	Change in expressive language as measured by total number of words used.	Change in total number or words used in a guided language sample. An increase in score indicates improvement.	Baseline to 12 weeks
Secondary	Change in adaptive skills as measured by the VABS-3 domain level standard score.	Change in standard scores for at least one domain in the Vineland Adaptive Behavior Scales-3 (VABS-3) between baseline and 12 weeks within or between treatment arms. An increase in standard score by domain indicates improvement.	Baseline to 12 weeks
Secondary	Change in family impact score as measured by summary score on PedsQL Family Impact Score.	Change in the Pediatric Quality of Life Inventory (PedsQL) within or between treatment arms. An increase in summary score indicates improvement.	Baseline to 12 weeks
Secondary	Change in quality of life score as measured by PedsQL summary score.	Change in the Pediatric Quality of Life Inventory (PedsQL) summary score within or between treatment arms. An increase in summary score indicates improvement.	Baseline to 12 weeks